High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
HBcrAg
HBeAg
HBsAg
Hepatic fibrosis
Hepatocellular carcinoma
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
27
09
2022
accepted:
08
02
2023
medline:
1
5
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Progressive hepatic fibrosis leads to hepatocellular carcinoma (HCC) and decompensated cirrhosis. The aim of this study was to identify the high-risk population for progressive hepatic fibrosis and the incidence of HCC and decompensated cirrhosis in chronic hepatitis B (CHB) patients with antiviral therapy. The data came from a multicenter, center-randomized, double-blind clinical trial that analyzed only patients in the ETV-treated arm. There was 156 hepatitis B e antigen (HBeAg)-positive and 135 HBeAg-negative patients in 14 institutions. The primary endpoint was fibrosis reversal on 72-week Entecavir (ETV) treatment. The 7-year cumulative incidence of HCC and decompensated cirrhosis were analyzed. Multivariate logistic and LASSO regression analyses were used to screen variables associated with fibrosis reversal. 86/156 (55%) HBeAg-positive and 58/135 (43%) HBeAg-negative patients achieved fibrosis reversal on 72-week ETV treatment. Average age was 43 years, 203 (69.8%) was male, and 144 (49.5%) patients had cirrhosis. Age ≥ 40 years (OR: 0.46, 95% CI 0.23-0.93) and HBcrAg ≥ 8.23 log U/ml (OR: 2.72, 95% CI 1.33-5.54) in HBeAg-positive patients and HBV genotype C (OR: 0.44, 95% CI 0.21-0.97) in HBeAg-negative patients were independent factors of fibrosis reversal. It was confirmed in patients with cirrhosis. After 7-year ETV treatment, seven (4.5%) HBeAg-positive patients occurred HCC or decompensated cirrhosis, including four patients with age ≥ 40 years and six with HBcrAg 8.23log U/ml, while twelve (8.9%) HBeAg-negative patients occurred, including eleven with HBV genotype C. HBeAg-positive patients with a low HBcrAg level or old age, and HBeAg-negative patients with HBV genotype C tended to develop progressive hepatic fibrosis and had a high incidence of HCC and decompensated cirrhosis, even on ETV treatment.
Sections du résumé
BACKGROUND
Progressive hepatic fibrosis leads to hepatocellular carcinoma (HCC) and decompensated cirrhosis. The aim of this study was to identify the high-risk population for progressive hepatic fibrosis and the incidence of HCC and decompensated cirrhosis in chronic hepatitis B (CHB) patients with antiviral therapy.
METHODS
The data came from a multicenter, center-randomized, double-blind clinical trial that analyzed only patients in the ETV-treated arm. There was 156 hepatitis B e antigen (HBeAg)-positive and 135 HBeAg-negative patients in 14 institutions. The primary endpoint was fibrosis reversal on 72-week Entecavir (ETV) treatment. The 7-year cumulative incidence of HCC and decompensated cirrhosis were analyzed. Multivariate logistic and LASSO regression analyses were used to screen variables associated with fibrosis reversal.
RESULTS
86/156 (55%) HBeAg-positive and 58/135 (43%) HBeAg-negative patients achieved fibrosis reversal on 72-week ETV treatment. Average age was 43 years, 203 (69.8%) was male, and 144 (49.5%) patients had cirrhosis. Age ≥ 40 years (OR: 0.46, 95% CI 0.23-0.93) and HBcrAg ≥ 8.23 log U/ml (OR: 2.72, 95% CI 1.33-5.54) in HBeAg-positive patients and HBV genotype C (OR: 0.44, 95% CI 0.21-0.97) in HBeAg-negative patients were independent factors of fibrosis reversal. It was confirmed in patients with cirrhosis. After 7-year ETV treatment, seven (4.5%) HBeAg-positive patients occurred HCC or decompensated cirrhosis, including four patients with age ≥ 40 years and six with HBcrAg 8.23log U/ml, while twelve (8.9%) HBeAg-negative patients occurred, including eleven with HBV genotype C.
CONCLUSIONS
HBeAg-positive patients with a low HBcrAg level or old age, and HBeAg-negative patients with HBV genotype C tended to develop progressive hepatic fibrosis and had a high incidence of HCC and decompensated cirrhosis, even on ETV treatment.
Identifiants
pubmed: 36928343
doi: 10.1007/s00535-023-01970-3
pii: 10.1007/s00535-023-01970-3
doi:
Substances chimiques
Antiviral Agents
0
Hepatitis B e Antigens
0
DNA, Viral
0
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
481-493Subventions
Organisme : Natural Science Foundation of Beijing Municipality
ID : 7212101
Organisme : Major Science and Technology Special Project of China
ID : 2018ZX10725-506
Informations de copyright
© 2023. Japanese Society of Gastroenterology.
Références
Péneau C, Imbeaud S, La Bella T, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2022;71:616–26.
doi: 10.1136/gutjnl-2020-323153
pubmed: 33563643
Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol. 2013;28:912–23.
doi: 10.1111/jgh.12213
pubmed: 23573915
Rong G, Chen Y, Yu Z, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: a multicenter, randomized, double-blind, placebo-controlled trial. J Infect Dis. 2022;225:1091–9.
doi: 10.1093/infdis/jiaa266
pubmed: 32437567
Tong XF, Wang QY, Zhao XY, et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin. 2022;43:1200–9.
doi: 10.1038/s41401-022-00874-x
pubmed: 35165400
Brunt EM. Liver biopsy reliability in clinical trials: thoughts from a liver pathologist. J Hepatol. 2020;73:1310–2.
doi: 10.1016/j.jhep.2020.08.014
pubmed: 32890594
Karlas T, Petroff D, Sasso M, et al. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther. 2018;47:989–1000.
doi: 10.1111/apt.14529
pubmed: 29446106
Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773–80.
doi: 10.1016/j.jhep.2015.11.012
pubmed: 26626497
Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naive, e antigen-positive patients. J Hepatol. 2013;58:1089–95.
doi: 10.1016/j.jhep.2013.01.028
pubmed: 23369792
Seto WK, Wong DK, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 2012;7: e43087.
doi: 10.1371/journal.pone.0043087
pubmed: 22916211
pmcid: 3423440
Tada T, Kumada T, Toyoda H, et al. HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics. J Hepatol. 2016;65:48–56.
doi: 10.1016/j.jhep.2016.03.013
pubmed: 27034253
Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615–25.
doi: 10.1016/j.jhep.2018.11.030
pubmed: 30529504
Huang D, Wu D, Wang P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77:42–54.
doi: 10.1016/j.jhep.2022.01.021
pubmed: 35149125
Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 2015;64:292–302.
doi: 10.1136/gutjnl-2014-306977
pubmed: 24763132
Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol. 2003;4:1277–9.
doi: 10.1128/JCM.41.3.1277-1279.2003
Qu J, Yu Z, Li Q, et al. Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial. Trials. 2014;15:438.
doi: 10.1186/1745-6215-15-438
pubmed: 25381721
pmcid: 4234899
Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B. J Hepatol. 2022;77:1515–24.
doi: 10.1016/j.jhep.2022.07.018
pubmed: 35985545
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.
doi: 10.1002/hep.29086
pubmed: 28130846
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (London, England). 2013;381:468–75.
doi: 10.1016/S0140-6736(12)61425-1
pubmed: 23234725
WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015.
Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017–44.
doi: 10.1002/hep.22742
pubmed: 19243014
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.
doi: 10.1016/0168-8278(95)80226-6
pubmed: 7560864
Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942–7.
doi: 10.1128/JCM.00366-07
pubmed: 17942661
pmcid: 2168562
Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439–45.
doi: 10.1128/JCM.40.2.439-445.2002
pubmed: 11825954
pmcid: 153363
Xu Z, Ren X, Liu Y, et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol. 2011;46:391–400.
doi: 10.1007/s00535-010-0315-4
pubmed: 20848146
Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022;20:2567-2576.e6.
doi: 10.1016/j.cgh.2021.12.034
pubmed: 34971806
Boursier J, de Ledinghen V, Leroy V, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66:1158–65.
doi: 10.1016/j.jhep.2017.01.003
pubmed: 28088581
Chang XJ, Sun C, Chen Y, et al. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol. 2019;25:4764–78.
doi: 10.3748/wjg.v25.i32.4764
pubmed: 31528100
pmcid: 6718032
Vachon A, Osiowy C. Novel biomarkers of hepatitis B virus and their use in chronic hepatitis B patient management. Viruses. 2021;13:951.
doi: 10.3390/v13060951
pubmed: 34064049
pmcid: 8224022
Wang W, Shu Y, Bao H, et al. Genotypes and hot spot mutations of hepatitis B virus in northwest Chinese population and its correlation with diseases progression. Biomed Res Int. 2019;2019:3890962.
doi: 10.1155/2019/3890962
pubmed: 31886206
pmcid: 6925797
Chu CM, Lin CC, Chen YC, et al. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection. Br J Cancer. 2012;107:2010–5.
doi: 10.1038/bjc.2012.474
pubmed: 23079574
pmcid: 3516680
Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology. 2013;57:441–50.
doi: 10.1002/hep.26041
pubmed: 22941922
Croagh CM, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int. 2010;30:1115–22.
doi: 10.1111/j.1478-3231.2010.02267.x
pubmed: 20492511
Ji D, Chen Y, Shang Q, et al. Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B. Am J Gastroenterol. 2021;116:1676–85.
doi: 10.14309/ajg.0000000000001239
pubmed: 33840727
pmcid: 8315185
Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157:1518-29.e3.
doi: 10.1053/j.gastro.2019.08.028
pubmed: 31470004
Liang LY, Wong VW, Toyoda H, et al. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol. 2020;55:899–908.
doi: 10.1007/s00535-020-01700-z
pubmed: 32556643
Hosaka T, Suzuki F, Kobayashi M, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther. 2019;49:457–71.
doi: 10.1111/apt.15108
pubmed: 30663078
Mak LY, Huang Q, Wong DK, et al. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2021;56:479–88.
doi: 10.1007/s00535-021-01780-5
pubmed: 33772643